| Document |
Document Title |
|
WO/2021/023117A1 |
Provided are an anti-CTLA4-anti-PD-1 bispecific antibody and uses thereof. The bispecific antibody comprises: a first protein functional area targeting PD-1 and a second protein functional area targeting CTLA4, where, according to the EU...
|
|
WO/2021/022676A1 |
Provided in the present application are an antibody against factor XIa in the activated form of coagulant factor XI, a preparation method therefor and the use thereof. The CDR of the heavy chain variable region of the antigen-binding fra...
|
|
WO/2021/019033A1 |
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxys...
|
|
WO/2021/021999A1 |
Provided herein are compositions and methods for increasing fetal hemoglobin in a subject in need thereof. Also provided are compositions and methods for treating a hemoglobin disorder in a subject.
|
|
WO/2021/019036A1 |
The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxys...
|
|
WO/2021/022161A1 |
Peptide nucleic acid (PNA) oligomers that target the β-globin gene and can increase the frequency of recombination of donor oligonucleotide at the site of a Sickle Cell Disease mutation are provided. Nanoparticle formulations for delive...
|
|
WO/2021/022189A1 |
The disclosure provide methods and compositions that use gene editing or gene therapy to treat alpha thalassemia major. The gene editing may be performed ex vivo in fetal cells or cells obtained after birth to improve production of globi...
|
|
WO/2021/021000A1 |
The invention relates to the field of chemistry and the chemical and pharmaceutical industry and concerns a novel method for the synthesis of the substance avatrombopag in the form of a base or a pharmaceutically acceptable salt. Avatrom...
|
|
WO/2021/021699A1 |
Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient havin...
|
|
WO/2021/021615A1 |
The present invention provides, among other things, methods and compositions for making and using recombinant heme oxygenase for treating sickle cell disease. In some embodiments, recombinant heme oxygenase proteins are truncation varian...
|
|
WO/2021/022132A1 |
Hematopoietic stem cell (HSC) transplantation is a promising treatment for patients with various hematological diseases, immunodeficiency, autoimmune disorders, and other genetic disorders. Considerable work continues to strive toward th...
|
|
WO/2021/021994A1 |
Methods for the treatment of sickle cell disease or complications associated therewith, including, for example, vaso-occlusive crisis, by the use of at least one E-selectin inhibitor and compositions comprising the same are disclosed.
|
|
WO/2021/018414A1 |
The present invention is related to a pharmaceutical composition for oral administration comprising a core comprising a pharmaceutically acceptable organic acid; optionally an isolating layer comprising a pharmaceutically acceptable poly...
|
|
WO/2021/014997A1 |
This perfusion method has: a cleaning step a) that cleans inside blood vessels by causing a first perfusion fluid to flow inside the blood vessels of an organ and then causing the perfusion fluid to be discharged outside the organ, via t...
|
|
WO/2021/013209A1 |
Macrocyclic derivatives, preparation methods therefor and pharmaceutical compositions comprising said derivatives, and uses thereof as therapeutic agents, especially as factor XIa inhibitors and in drugs for treating and preventing throm...
|
|
WO/2021/013131A1 |
Provided herein are hemoglobin-based therapeutic agents useful for treating cancer, pharmaceutical composition including the same, and methods of use and preparation thereof.
|
|
WO/2021/008014A1 |
Disclosed are a spiro (3,3'-phenylpyrrolidine oxyindole) liver X receptor modulator, a preparation method and an application, the receptor modulator specifically being a compound represented by formula (I), or a stereoisomer, geometric i...
|
|
WO/2021/005169A1 |
The invention pertains platelet endothelial aggregation receptor 1 (PEAR1) agonist for use in the treatment of bleeding in a patient wherein the patient is under antiplatelet medication. Provided is also a topical haemostat, a sealant, o...
|
|
WO/2021/007189A1 |
Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide
acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.
|
|
WO/2021/002481A1 |
The purpose of the present invention is to provide a drug delivery carrier which can be accumulated selectively in the kidney in vivo and which can show high biodegrability and drug-release capability in the kidney. The present invention...
|
|
WO/2021/002686A1 |
The present invention relates to a composition for preventing, alleviating or treating hyperuricemia or hyperuricemia-associated metabolic disorders, containing eggshell membrane as an active ingredient. Eggshell membrane, which is the a...
|
|
WO/2021/000247A1 |
Disclosed are a strain for producing nattokinase and a production method therefor. In particular, the present invention involves a new strain capable of producing nattokinase, i.e. Bacillus subtilis natto ST-1086, deposited at the China ...
|
|
WO/2021/000767A1 |
Provided are a blood coagulation factor IX fusion protein with a prolonged circulation half-life, a conjugate thereof, a pharmaceutical composition containing same and the use of same in treating hemorrhagic diseases (such as hemophilia B).
|
|
WO/2020/262004A1 |
[Problem] The purpose of the present invention is to provide a technique which suppresses degradation in the activity of nattokinase with time in an oral composition that comprises nattokinase, and which imparts excellent storage stabili...
|
|
WO/2020/259668A1 |
A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.
|
|
WO/2020/264488A1 |
Methods and compositions for producing heme and treating sideroblastic anemia are disclosed.
|
|
WO/2020/259109A1 |
Provided by the present invention is a fusion protein of plant-produced oral EPO and transferrin, using a plant such as lettuce as an expression platform for recombinant protein production. Further provided is an application of the fusio...
|
|
WO/2020/259366A1 |
Disclosed are a crystal form of a coagulation factor XIa inhibitor and a preparation method therefor, wherein the X-ray powder diffraction pattern of the crystal form comprises diffraction peaks of the 2θ angle at 6.9±0.2°, 15.9±0.2Â...
|
|
WO/2020/263729A1 |
A method of promoting new tissue regeneration and wound healing in a mammal by inhibiting production of at least one of inflammatory cells, neutrophils, macrophages, and leukocyte lineages in a wound area, limiting inflammation of the wo...
|
|
WO/2020/262184A1 |
Provided is a novel method for inhibiting myostatin.　An antisense oligonucleotide having a base length of 15-30 that has a base sequence complementary to the target site of exon 1 of myostatin gene, a salt thereof or a solvate of the s...
|
|
WO/2020/259673A1 |
Disclosed is a method for efficiently screening fibrinogen by using a phage antibody library, comprising the steps of: coating a protein, sealing a flat plate, removing a background from a phage library, combining phage and the like. Com...
|
|
WO/2020/256795A1 |
The present disclosure relates to methods of treating neointimal hyperplasia. The methods include selecting a subject having a blood vessel abnormality, and administering to the subject an amount of a composition, wherein the composition...
|
|
WO/2020/253802A1 |
A use of a diarylamide compound having the structure as shown in formula (I) or a pharmaceutically acceptable salt thereof in preparing a drug which acts as a urea transporter protein inhibitor, and a novel diarylamide compound. The diar...
|
|
WO/2020/256017A1 |
[Problem] To provide a milky plasma improving agent and a prophylactic or ameliorating agent for chylomicronemia. [Solution] Red yeast rice or a processed product thereof is contained as an active ingredient.
|
|
WO/2020/254427A1 |
The invention provides an alginate oligomer for use in the anticoagulation therapy of a human or non-human vertebrate subject at risk of blood clots which have an abnormally dense microstructure. In certain embodiments, the incidence of ...
|
|
WO/2020/254619A1 |
Protease nexin-1 (PN-1) is a member of the serine protease inhibitor (Serpin)-family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN-1 frequently cross-react with Plasminogen activator inhibitor...
|
|
WO/2020/253882A1 |
Disclosed are a series of isoquinolinone derivatives as ROCK protein kinase inhibitors and use thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specifically, disclosed a...
|
|
WO/2020/257720A1 |
The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said p...
|
|
WO/2020/257325A1 |
The disclosure features methods of correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene ...
|
|
WO/2020/251924A1 |
The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful f...
|
|
WO/2020/249977A1 |
The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a pati...
|
|
WO/2020/249712A1 |
The present invention relates to the field of treating iron deficiency with intravenous iron carbohydrate complexes such iron isomaltoside in subjects at risk of a cardiovascular adverse event, wherein the treatment of iron deficiency re...
|
|
WO/2020/251887A1 |
Described herein are methods and compositions related to GATA-1 gene therapy for the treatment of Diamond-Blackfan anemia.
|
|
WO/2020/251748A1 |
The present invention is directed to a novel treatment for Wolfram Syndrome or heterozygous wolframin, to methods of treatment in order to delay, inhibit, ameliorate and/or reduce the likelihood of symptomology of a patient with Wolfram ...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/247746A1 |
The disclosure provides a method for treating sickle cell disease with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-mediated von Will...
|
|
WO/2020/246581A1 |
The present invention addresses the problem of providing a lipid composition which enables excellent nucleic acid delivery. According to the present invention, a lipid composition is provided, which contains a lipid represented by formul...
|
|
WO/2020/243105A1 |
The present disclosure relates to a method of culturing quiescent hematopoietic stem cells. This method involves providing a culture medium and introducing, into the culture medium, quiescent hematopoietic stem cells to culture the stem ...
|
|
WO/2020/237304A1 |
Disclosed are antigen-binding molecules that bind to activated platelets and inhibit platelet function, including platelet aggregation and thrombus formation. More particularly, antigen-binding molecules are disclosed that bind to the ac...
|
|
WO/2020/242231A1 |
The present invention relates to a hemostatic composition and a receptacle comprising same, the hemostatic composition comprising collagen, a stabilizer and thrombin. The hemostatic composition and the receptacle comprising same may be a...
|
